Company intelligence / Profile preview

Kiniksa Pharmaceuticals

Ownership: Public · KNSA
Development stage: Other

Overview

ARCALYST has shown strong market performance with 75% year-over-year growth in Q1 2025, generating $137.8 million in net product revenue. The company reported a net income of $8.5 million in Q1 2025 compared to a $17.7 million loss in the same period last year. Over 3,150 prescribers have written prescriptions for recurrent pericarditis since launch, with average therapy duration extending to approximately 30 months[6].

Therapeutic areas: CardiovascularRheumatologyImmunologyDermatologyInfectious Diseases
Modalities: Monoclonal antibodiesIL-1 receptor antagonists
Industry: Biotech

Drug pipeline

8 assets

rilonacept

Approved

7 more assets in the full pipeline.

Partnerships

Huadong Medicine (exclusive rights in the Asia Pacific Region)

Financials

Market cap: $6.9B
Total revenue: $677.6M
Enterprise value: $6.4B

Beyond the preview

Go deeper on Kiniksa Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kiniksa Pharmaceuticals.